Within the pharmaceutical industry, a multibillion-dollar race is underway to top Novo Nordisk’s and Eli Lilly’s in-demand obesity drugs. Dozens of companies, large and small, have set out to test ...

While shares have posted break-even returns so far in 2024, Pfizer stock has cratered by more than 30% over the ...

Pfizer Inc.'s stock gained Monday after a report that activist investor Starboard Value has invested $1 billion in the drug company. Bondholders seem to like the news too. Spreads on the company's ...

Three Motley Fool contributors believe they have identified magnificent dividend stocks to buy in October -- and all of them are drugmakers. Here's why they picked AbbVie ( ABBV -0.59%), Amgen ( AMGN ...

Drug Development & Delivery Publishes Overview of Obesity Formulation Development Results Demonstrating Significant Transdermal Penetration Using Invisicare Technology. LAS VEGAS, ...

Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

Analysts were impressed with yesterday’s data drop, with BMO Capital Markets comparing TERN-601 to oral competitors such as Eli Lilly’s orforglipron and Pfizer’s danuglipron. After just 28 days, ...

The trial assessed TERN-601 in healthy adults with obesity or who are overweight. Credit: earth phakphum / Shutterstock. US-based biopharmaceutical company Terns Pharmaceuticals has reported positive ...

The company is axing twice-daily oral GLP-1 receptor agonist danuglipron and instead will switch to a once-daily version of the drug codenamed PF-06882961. It said patients taking the drug had ...

Proactive Oil and Gas highlights: Nostra Oil, Touchstone Energy, Jersey Oil ...